Clinical significance of hematocrit interference in the tacrolimus II microparticle enzyme immunoassay: A tentative approach

Clinical Laboratory

Volumn 51, Issue 1-2, 2005, Pages 43-45

  Hermida, Jesús ^a   Concepcion Fernandez M ^a   Tutor, Jose Carlos ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Clinical practice; Hematocrit interference; MEIA; Microparticle enzyme immunoassay; Tacrolimus

Indexed keywords

TACROLIMUS;

ACCURACY; ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; VALIDATION PROCESS;

ARTIFACTS; CLINICAL MEDICINE; DRUG MONITORING; HEMATOCRIT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 13844319479     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry / International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group of Immunosuppressive Drug Monitoring. Ther Drug Monit 2002; 24: 59-67.
2. Homma M, Tomita T, Yuzawa K, Takada Y, Kohda Y. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull 2002; 25: 111-20.
3. Doyen C, Revenant MC. Évaluation du réactif Tacrolimus EMIT® 2000 (Dade Behring) et comparaison an réactif Imx® Tacrolimus II (Abbott) dans la suivi des transplantes hépatiques. Immunoanal Biol Spéc 2003; 18: 360-64.
4. Kuzuya T, Ogura Y, Motegi Y, Moriyama N, Nabeshima T. Interference of hematocrit in the Tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit 2002; 24: 507-11.
5. Taylor PJ, Morris RG. Tacrolimus measurement by microparticle enzyme immunoassay II (Editorial). Ther Drug Monit 2003; 25: 259-60.
6. Shah VP, Midha KK, Dighe S, Mc Gilveray IJ, Skelly JP, Yacobi A et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference Report. Eur J Drug Metab Pharmacokin 1991; 16: 249-55.
7. Schambeck CM, Bedel A, Keller F. Limit of quantification (functional sensitivity) of the new IMx Tacrolimus II microparticle enzyme immunoassay. Clin Chem 1998; 44: 2217.
8. Hermida J., Tutor JC. More on the reliability of the microparticle enzyme immunoassay (MEIA) for therapeutic tacrolimus monitoring. Clin Lab 2003; 49: 471-74.
9. Steele BW, Wnag E, Soldin SJ, Klee G, Elin RS, Witte DL. A longitudinal replicate study of immunosuppressive drugs. A College of American Pathologists Study. Arch Pathol Lab Med 2003; 127: 283-88.